ABT-199 (venetoclax) is FDA approved for the treatment of some hematologic malignancies, but the use of BH3 mimetics targeting Bcl-xL—such as A-1331852—would need to undergo further safety and toxicity studies in combination with radiotherapy to identify and mitigate any potential overlapping toxicities. The gene discussed is BCL2L1; the disease is hematologic disorder.